Razuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP. In investigations against diabetes and COVID-19, razuprotafib is self-administered by patients through subcutaneous injection.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.